View Item 

Show simple item record

Systematic review: cardiovascular safety profile of 5‐ HT 4 agonists developed for gastrointestinal disorders

dc.contributor.authorTack, J. F.en_US
dc.contributor.authorCamilleri, Michaelen_US
dc.contributor.authorChang, L.en_US
dc.contributor.authorChey, William D.en_US
dc.contributor.authorGalligan, J. J.en_US
dc.contributor.authorLacy, B. E.en_US
dc.contributor.authorMüller‐lissner, S.en_US
dc.contributor.authorQuigley, Eamonn M. M.en_US
dc.contributor.authorSchuurkes, J.en_US
dc.contributor.authorMaeyer, J. H.en_US
dc.contributor.authorStanghellini, V.en_US
dc.date.accessioned2012-04-04T18:43:01Z
dc.date.available2013-06-11T19:15:42Zen_US
dc.date.issued2012-04en_US
dc.identifier.citationTack, J.; Camilleri, M.; Chang, L.; Chey, W. D.; Galligan, J. J.; Lacy, B. E.; Müller‐lissner, S. ; Quigley, E. M. M.; Schuurkes, J.; Maeyer, J. H.; Stanghellini, V. (2012). "Systematic review: cardiovascular safety profile of 5â HT 4 agonists developed for gastrointestinal disorders." Alimentary Pharmacology & Therapeutics (7): 745-767. <http://hdl.handle.net/2027.42/90554>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90554
dc.publisherWiley Periodicals, Inc.en_US
dc.titleSystematic review: cardiovascular safety profile of 5‐ HT 4 agonists developed for gastrointestinal disordersen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid22356640en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90554/1/apt5011.pdf
dc.identifier.doi10.1111/j.1365-2036.2012.05011.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceRuth M, Finizia C, Cange L, Lundell L. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro‐oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003; 15: 1115 – 21.en_US
dc.identifier.citedreferenceThumshirn M, Fruehauf H, Stutz B, Tougas G, Salter J, Fried M. Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia. Aliment Pharmacol Ther 2007; 26: 1399 – 407.en_US
dc.identifier.citedreferenceBouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120: 354 – 60.en_US
dc.identifier.citedreferenceElorza JM, Capdevila C. Double‐blind parallel comparison of the gastrokinetic effects of clebopride, domperidone and placebo in human volunteers with gastric stasis induced by glucagon. Curr Ther Res 1982; 31: S58 – 60.en_US
dc.identifier.citedreferenceVerhagen MA, Roelofs JM, Edelbroek MA, Smout AJ, Akkermans LM. The effect of cisapride on duodenal acid exposure in the proximal duodenum in healthy subjects. Aliment Pharmacol Ther 1999; 13: 621 – 30.en_US
dc.identifier.citedreferenceRezende‐Filho J, Di Lorenzo C, Dooley CP, Valenzuela JE. Cisapride stimulates antral motility and decreases biliary reflux in patients with severe dyspepsia. Dig Dis Sci 1989; 34: 1057 – 62.en_US
dc.identifier.citedreferenceTestoni PA, Bagnolo F, Fanti L, Passaretti S, Tittobello A. Longterm oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients. Gut 1990; 31: 286 – 90.en_US
dc.identifier.citedreferenceVaezi MF, Sears R, Richter JE. Placebo‐controlled trial of cisapride in postgastrectomy patients with duodenogastroesophageal reflux. Dig Dis Sci 1996; 41: 754 – 63.en_US
dc.identifier.citedreferenceMarzio L, DiGiammarco AM, Capone F, et al. Effect of cisapride on human fasting gallbladder volume: a real‐time ultrasonographic study. Eur J Clin Pharmacol 1986; 29: 631 – 3.en_US
dc.identifier.citedreferenceTakaoka M, Kubota Y, Fujimura K, et al. Effect of single and multiple administrations of cisapride on postprandial gallbladder emptying in healthy humans. Intern Med 1994; 33: 381 – 6.en_US
dc.identifier.citedreferenceCoremans G, Janssens J, Vantrappen G, Chaussade S, Ceccatelli P. Cisapride stimulates propulsive motility patterns in human jejunum. Dig Dis Sci 1988; 33: 1512 – 9.en_US
dc.identifier.citedreferenceEvans PR, Bak YT, Kellow JE. Effects of oral cisapride on small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 837 – 44.en_US
dc.identifier.citedreferenceStacher G, Gaupmann G, Mittelbach G, Schneider C, Steinringer H, Langer B. Effects of oral cisapride on interdigestive jejunal motor activity, psychomotor function, and side‐effect profile in healthy man. Dig Dis Sci 1987; 32: 1223 – 30.en_US
dc.identifier.citedreferenceStacher G, Steinringer H, Schneider C, Winklehner S, Mittelbach G, Gaupmann G. Effects of cisapride on jejunal motor activity in fasting healthy humans. Gastroenterology 1986; 90: 1210 – 6.en_US
dc.identifier.citedreferenceNoor N, Small PK, Loudon MA, Hau C, Campbell FC. Effects of cisapride on symptoms and postcibal small‐bowel motor function in patients with irritable bowel syndrome. Scand J Gastroenterol 1998; 33: 605 – 11.en_US
dc.identifier.citedreferenceCamilleri M, Brown ML, Malagelada JR. Impaired transit of chyme in chronic intestinal pseudoobstruction. Correction by cisapride. Gastroenterology 1986; 91: 619 – 26.en_US
dc.identifier.citedreferenceKrevsky B, Malmud LS, Maurer AH, Somers MB, Siegel JA, Fisher RS. The effect of oral cisapride on colonic transit. Aliment Pharmacol Ther 1987; 1: 293 – 304.en_US
dc.identifier.citedreferenceBak YT, Kim JH, Lee CH. Cisapride in chronic idiopathic constipation: clinical response and effect on colonic transit time. Korean J Intern Med 1996; 11: 151 – 6.en_US
dc.identifier.citedreferenceKrevsky B, Maurer AH, Malmud LS, Fisher RS. Cisapride accelerates colonic transit in constipated patients with colonic inertia. Am J Gastroenterol 1989; 84: 882 – 7.en_US
dc.identifier.citedreferenceJost WH, Schimrigk K. The effect of cisapride on delayed colonic transit time in patients with idiopathic Parkinson's disease. Wien Klin Wochenschr 1994; 106: 673 – 6.en_US
dc.identifier.citedreferenceGeders JM, Gaing A, Bauman WA, Korsten MA. The effect of cisapride on segmental colonic transit time in patients with spinal cord injury. Am J Gastroenterol 1995; 90: 285 – 9.en_US
dc.identifier.citedreferenceRoberts JP, Benson MJ, Rogers J, Deeks JJ, Wingate DL, Williams NS. Effect of cisapride on distal colonic motility in the early postoperative period following left colonic anastomosis. Dis Colon Rectum 1995; 38: 139 – 45.en_US
dc.identifier.citedreferencePoen AC, Felt‐Bersma RJ, Van Dongen PA, Meuwissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999; 13: 1493 – 7.en_US
dc.identifier.citedreferenceSloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002; 16: 759 – 67.en_US
dc.identifier.citedreferenceCoffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D. Tegaserod, a 5‐HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17: 577 – 85.en_US
dc.identifier.citedreferenceSanger GJ, Alpers DH. Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol Motil 2008; 20: 177 – 84.en_US
dc.identifier.citedreferenceBriejer MR, Akkermans LM, Schuurkes JA. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995; 47: 631 – 51.en_US
dc.identifier.citedreferenceLanglois M, Fischmeister R. 5‐HT4 receptor ligands: applications and new prospects. J Med Chem 2003; 46: 319 – 44.en_US
dc.identifier.citedreferenceEvans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007; CD003960.en_US
dc.identifier.citedreferenceMcCallum RW, Prakash C, Campoli‐Richards DM, Goa KL. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 1988; 36: 652 – 81.en_US
dc.identifier.citedreferenceNovartis. Press release: Novartis suspends US marketing and sales of Zelnorm in response to request from FDA. Available at: http://hugin.info/134323/R/1116336/204121.pdf. Accessed December 14, 2010.en_US
dc.identifier.citedreferenceDrolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug‐related lengthening of the QT interval. Circulation 1998; 97: 204 – 10.en_US
dc.identifier.citedreferenceJones JK, Fife D, Curkendall S, Goehring E Jr, Guo JJ, Shannon M. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 2001; 286: 1607 – 9.en_US
dc.identifier.citedreferenceUS Food & Drug Administration. Zelnorm (tegaserod maleate). April 2009. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm. Accessed December 14, 2010.en_US
dc.identifier.citedreferenceDepartment of Health. Medicines Control Agency announces withdrawal of Cisapride July 2000. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Pressreleases/DH_4005066. Accessed December 14, 2010.en_US
dc.identifier.citedreferenceDumuis A, Sebben M, Bockaert J. The gastrointestinal prokinetic benzamide derivatives are agonists at the non‐classical 5‐HT receptor (5‐HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 403 – 10.en_US
dc.identifier.citedreferenceMarkstein R, Matsumoto M, Kohler C, Togashi H, Yoshioka M, Hoyer D. Pharmacological characterisation of 5‐HT receptors positively coupled to adenylyl cyclase in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1999; 359: 454 – 9.en_US
dc.identifier.citedreferenceBlondel O, Gastineau M, Dahmoune Y, Langlois M, Fischmeister R. Cloning, expression, and pharmacology of four human 5‐hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J Neurochem 1998; 70: 2252 – 61.en_US
dc.identifier.citedreferenceMedhurst AD, Lezoualc'h F, Fischmeister R, Middlemiss DN, Sanger GJ. Quantitative mRNA analysis of five C‐terminal splice variants of the human 5‐HT4 receptor in the central nervous system by TaqMan real time RT‐PCR. Brain Res Mol Brain Res 2001; 90: 125 – 34.en_US
dc.identifier.citedreferenceClaeysen S, Faye P, Sebben M, Taviaux S, Bockaert J, Dumuis A. 5‐HT4 receptors: cloning and expression of new splice variants. Ann N Y Acad Sci 1998; 861: 49 – 56.en_US
dc.identifier.citedreferenceRay AM, Kelsell RE, Houp JA, et al. Identification of a novel 5‐HT(4) receptor splice variant (r5‐HT(4c1)) and preliminary characterisation of specific 5‐HT(4a) and 5‐HT(4b) receptor antibodies. Eur J Pharmacol 2009; 604: 1 – 11.en_US
dc.identifier.citedreferenceDe Maeyer JH, Aerssens J, Verhasselt P, Lefebvre RA. Alternative splicing and exon duplication generates 10 unique porcine 5‐HT 4 receptor splice variants including a functional homofusion variant. Physiol Genomics 2008; 34: 22 – 33.en_US
dc.identifier.citedreferenceBender E, Pindon A, van Oers I, et al. Structure of the human serotonin 5‐HT4 receptor gene and cloning of a novel 5‐HT4 splice variant. J Neurochem 2000; 74: 478 – 89.en_US
dc.identifier.citedreferenceClaeysen S, Sebben M, Becamel C, Bockaert J, Dumuis A. Novel brain‐specific 5‐HT4 receptor splice variants show marked constitutive activity: role of the C‐terminal intracellular domain. Mol Pharmacol 1999; 55: 910 – 20.en_US
dc.identifier.citedreferenceLiu M, Geddis MS, Wen Y, Setlik W, Gershon MD. Expression and function of 5‐HT4 receptors in the mouse enteric nervous system. Am J Physiol Gastrointest Liver Physiol 2005; 289: G1148 – 63.en_US
dc.identifier.citedreferencevan Lelyveld N, Ter Linde J, Schipper M, Samsom M. Serotonergic signalling in the stomach and duodenum of patients with gastroparesis. Neurogastroenterol Motil 2008; 20: 448 – 55.en_US
dc.identifier.citedreferenceMatsumoto M, Togashi H, Mori K, et al. Evidence for involvement of central 5‐HT(4) receptors in cholinergic function associated with cognitive processes: behavioral, electrophysiological, and neurochemical studies. J Pharmacol Exp Ther 2001; 296: 676 – 82.en_US
dc.identifier.citedreferenceYan Z. Regulation of GABAergic inhibition by serotonin signaling in prefrontal cortex: molecular mechanisms and functional implications. Mol Neurobiol 2002; 26: 203 – 16.en_US
dc.identifier.citedreferenceAlex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007; 113: 296 – 320.en_US
dc.identifier.citedreferenceBrattelid T, Qvigstad E, Lynham JA, et al. Functional serotonin 5‐HT4 receptors in porcine and human ventricular myocardium with increased 5‐HT4 mRNA in heart failure. Naunyn Schmiedebergs Arch Pharmacol 2004; 370: 157 – 66.en_US
dc.identifier.citedreferenceDe Maeyer JH, Schuurkes JA, Lefebvre RA. Selective desensitization of the 5‐HT4 receptor‐mediated response in pig atrium but not in stomach. Br J Pharmacol 2009; 156: 362 – 76.en_US
dc.identifier.citedreferenceDe Maeyer JH, Lefebvre RA, Schuurkes JA. 5‐HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008; 20: 99 – 112.en_US
dc.identifier.citedreferenceBaxter GS, Craig DA, Clarke DE. 5‐Hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae. Naunyn Schmiedebergs Arch Pharmacol 1991; 343: 439 – 46.en_US
dc.identifier.citedreferencePrins NH, Van Haselen JF, Lefebvre RA, Briejer MR, Akkermans LM, Schuurkes JA. Pharmacological characterization of 5‐HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol 1999; 127: 1431 – 7.en_US
dc.identifier.citedreferencePrins NH, Shankley NP, Welsh NJ, et al. An improved in vitro bioassay for the study of 5‐HT(4) receptors in the human isolated large intestinal circular muscle. Br J Pharmacol 2000; 129: 1601 – 8.en_US
dc.identifier.citedreferenceEglen RM, Swank SR, Walsh LK, Whiting RL. Characterization of 5‐HT3 and ‘atypical’ 5‐HT receptors mediating guinea‐pig ileal contractions in vitro. Br J Pharmacol 1990; 101: 513 – 20.en_US
dc.identifier.citedreferenceKilbinger H, Gebauer A, Haas J, Ladinsky H, Rizzi CA. Benzimidazolones and renzapride facilitate acetylcholine release from guinea‐pig myenteric plexus via 5‐HT4 receptors. Naunyn Schmiedebergs Arch Pharmacol 1995; 351: 229 – 36.en_US
dc.identifier.citedreferenceKilbinger H, Wolf D. Effects of 5‐HT4 receptor stimulation on basal and electrically evoked release of acetylcholine from guinea‐pig myenteric plexus. Naunyn Schmiedebergs Arch Pharmacol 1992; 345: 270 – 5.en_US
dc.identifier.citedreferencePan H, Galligan JJ. 5‐HT1A and 5‐HT4 receptors mediate inhibition and facilitation of fast synaptic transmission in enteric neurons. Am J Physiol 1994; 266: G230 – 8.en_US
dc.identifier.citedreferenceRen J, Zhou X, Galligan JJ. 5‐HT4 receptor activation facilitates recovery from synaptic rundown and increases transmitter release from single varicosities of myenteric neurons. Am J Physiol Gastrointest Liver Physiol 2008; 294: G1376 – 83.en_US
dc.identifier.citedreferenceLeclere PG, Lefebvre RA. Presynaptic modulation of cholinergic neurotransmission in the human proximal stomach. Br J Pharmacol 2002; 135: 135 – 42.en_US
dc.identifier.citedreferenceLeclere PG, Prins NH, Schuurkes JA, Lefebvre RA. 5‐HT4 receptors located on cholinergic nerves in human colon circular muscle. Neurogastroenterol Motil 2005; 17: 366 – 75.en_US
dc.identifier.citedreferenceDe Maeyer JH, Prins NH, Schuurkes JA, Lefebvre RA. Differential effects of 5‐hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ‐specific behavior. J Pharmacol Exp Ther 2006; 317: 955 – 64.en_US
dc.identifier.citedreferencePotet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether‐a‐gogo K(+) channel. J Pharmacol Exp Ther 2001; 299: 1007 – 12.en_US
dc.identifier.citedreferenceNagakura Y, Akuzawa S, Miyata K, et al. Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5‐HT4 receptor versus human 5‐HT3 receptor. Pharmacol Res 1999; 39: 375 – 82.en_US
dc.identifier.citedreferenceMohammad S, Zhou Z, Gong Q, January CT. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997; 273: H2534 – 8.en_US
dc.identifier.citedreferenceMine Y, Yoshikawa T, Oku S, Nagai R, Yoshida N, Hosoki K. Comparison of effect of mosapride citrate and existing 5‐HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. J Pharmacol Exp Ther 1997; 283: 1000 – 8.en_US
dc.identifier.citedreferenceWardle KA, Sanger GJ. The guinea‐pig distal colon–a sensitive preparation for the investigation of 5‐HT4 receptor‐mediated contractions. Br J Pharmacol 1993; 110: 1593 – 9.en_US
dc.identifier.citedreferenceCamilleri M, Vazquez‐Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5‐HT receptor agonist, ATI‐7505, in humans. Neurogastroenterol Motil 2007; 19: 30 – 8.en_US
dc.identifier.citedreferenceDennis D, Palme M, Irwin I, Druzgala P, Teichman S. ATI‐7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dogs. Gastroenterology 2004; 126: A641.en_US
dc.identifier.citedreferenceBeattie DT, Smith JA, Marquess D, et al. The 5‐HT4 receptor agonist, tegaserod, is a potent 5‐HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol 2004; 143: 549 – 60.en_US
dc.identifier.citedreferenceMcCullough JL, Armstrong SR, Hegde SS, Beattie DT. The 5‐HT2B antagonist and 5‐HT4 agonist activities of tegaserod in the anaesthetized rat. Pharmacol Res 2006; 53: 353 – 8.en_US
dc.identifier.citedreferenceGrider JR, Foxx‐Orenstein AE, Jin JG. 5‐Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115: 370 – 80.en_US
dc.identifier.citedreferenceBuchheit KH, Gamse R, Giger R, et al. The serotonin 5‐HT4 receptor. 2. Structure‐activity studies of the indole carbazimidamide class of agonists. J Med Chem 1995; 38: 2331 – 8.en_US
dc.identifier.citedreferenceBuchheit KH, Gamse R, Giger R, et al. The serotonin 5‐HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site. J Med Chem 1995; 38: 2326 – 30.en_US
dc.identifier.citedreferenceEmmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998; 42: 511 – 6.en_US
dc.identifier.citedreferenceBriejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil 2001; 13: 465 – 72.en_US
dc.identifier.citedreferenceBouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999; 44: 682 – 6.en_US
dc.identifier.citedreferenceBriejer MR, Bosmans JP, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001; 423: 71 – 83.en_US
dc.identifier.citedreferenceSmith JA, Beattie DT, Marquess D, Shaw JP, Vickery RG, Humphrey PP. The in vitro pharmacological profile of TD‐5108, a selective 5‐HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008; 378: 125 – 37.en_US
dc.identifier.citedreferenceBeattie DT, Armstrong SR, Shaw JP, et al. The in vivo gastrointestinal activity of TD‐5108, a selective 5‐HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008; 378: 139 – 47.en_US
dc.identifier.citedreferenceRao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010; 31: 11 – 9.en_US
dc.identifier.citedreferenceWager E, Tooley PJ, Pearce GL, Wilton LV, Mann RD. A comparison of two cohort studies evaluating the safety of cisapride: Prescription‐Event Monitoring and a large phase IV study. Eur J Clin Pharmacol 1997; 52: 87 – 94.en_US
dc.identifier.citedreferenceWalker AM, Szneke P, Weatherby LB, et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999; 107: 356 – 62.en_US
dc.identifier.citedreferenceLevy J, Hayes C, Kern J, et al. Does cisapride influence cardiac rhythm? Results of a United States multicenter, double‐blind, placebo‐controlled pediatric study. J Pediatr Gastroenterol Nutr 2001; 32: 458 – 63.en_US
dc.identifier.citedreferenceDalby‐Payne JR, Morris AM, Craig JC. Meta‐analysis of randomized controlled trials on the benefits and risks of using cisapride for the treatment of gastroesophageal reflux in children. J Gastroenterol Hepatol 2003; 18: 196 – 202.en_US
dc.identifier.citedreferenceOlsson S, Edwards IR. Tachycardia during cisapride treatment. BMJ 1992; 305: 748 – 9.en_US
dc.identifier.citedreferenceSmalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000; 284: 3036 – 9.en_US
dc.identifier.citedreferenceGross AS, Goh YD, Addison RS, Shenfield GM. Influence of grapefruit juice on cisapride pharmacokinetics. Clin Pharmacol Ther 1999; 65: 395 – 401.en_US
dc.identifier.citedreferenceHancox JC, James AF. Refining insights into high‐affinity drug binding to the human ether‐a‐go‐go‐related gene potassium channel. Mol Pharmacol 2008; 73: 1592 – 5.en_US
dc.identifier.citedreferenceDi Diego JM, Belardinelli L, Antzelevitch C. Cisapride‐induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 2003; 108: 1027 – 33.en_US
dc.identifier.citedreferenceChhina S, Peverini RL, Deming DD, Hopper AO, Hashmi A, Vyhmeister NR. QTc interval in infants receiving cisapride. J Perinatol 2002; 22: 144 – 8.en_US
dc.identifier.citedreferenceTreluyer JM, Rey E, Sonnier M, Pons G, Cresteil T. Evidence of impaired cisapride metabolism in neonates. Br J Clin Pharmacol 2001; 52: 419 – 25.en_US
dc.identifier.citedreferenceCools F, Benatar A, Bruneel E, et al. A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants. Eur J Clin Pharmacol 2003; 59: 17 – 22.en_US
dc.identifier.citedreferenceKyrmizakis DE, Chimona TS, Kanoupakis EM, Papadakis CE, Velegrakis GA, Helidonis ES. QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin. Am J Otolaryngol 2002; 23: 303 – 7.en_US
dc.identifier.citedreferenceEvans AJ, Krentz AJ. Should cisapride be avoided in patients with diabetic gastroparesis? J Diabetes Complications 1999; 13: 314 – 5.en_US
dc.identifier.citedreferenceGray VS. Syncopal episodes associated with cisapride and concurrent drugs. Ann Pharmacother 1998; 32: 648 – 51.en_US
dc.identifier.citedreferenceHatlebakk JG, Johnsson F, Vilien M, Carling L, Wetterhus S, Thogersen T. The effect of cisapride in maintaining symptomatic remission in patients with gastro‐oesophageal reflux disease. Scand J Gastroenterol 1997; 32: 1100 – 6.en_US
dc.identifier.citedreferenceLander A, Redkar R, Nicholls G, et al. Cisapride reduces neonatal postoperative ileus: randomised placebo controlled trial. Arch Dis Child Fetal Neonatal Ed 1997; 77: F119 – 22.en_US
dc.identifier.citedreferenceMuller‐Lissner SA. Treatment of chronic constipation with cisapride and placebo. Gut 1987; 28: 1033 – 8.en_US
dc.identifier.citedreferenceNurko S, Garcia‐Aranda JA, Worona LB, Zlochisty O. Cisapride for the treatment of constipation in children: A double‐blind study. J Pediatr 2000; 136: 35 – 40.en_US
dc.identifier.citedreferenceTack J, Muller‐Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol 2009; 7: 502 – 8.en_US
dc.identifier.citedreferenceQuigley EM, Wald A, Fidelholtz J, Boivin M, Pecher E, Earnest D. Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies. Clin Gastroenterol Hepatol 2006; 4: 605 – 13.en_US
dc.identifier.citedreferenceFock‐Kwong M, Wagner A. Safety, tolerability and satisfaction with tegaserod therapy in Asia‐Pacific patients with irritable bowel syndrome with constipation. J Gastroenterol Hepatol 2007; 22: 1190 – 8.en_US
dc.identifier.citedreferenceFried M, Beglinger C, Bobalj NG, Minor N, Coello N, Michetti P. Tegaserod is safe, well tolerated and effective in the treatment of patients with non‐diarrhoea irritable bowel syndrome. Eur J Gastroenterol Hepatol 2005; 17: 421 – 7.en_US
dc.identifier.citedreferenceTougas G, Snape WJ Jr, Otten MH, et al. Long‐term safety of tegaserod in patients with constipation‐predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 1701 – 8.en_US
dc.identifier.citedreferenceMuller‐Lissner S, Kamm MA, Musoglu A, Earnest DL, Dunger‐Baldauf C, Shetzline MA. Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation. Am J Gastroenterol 2006; 101: 2558 – 69.en_US
dc.identifier.citedreferenceSchoenfeld P. Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials. Aliment Pharmacol Ther 2004; 19: 263 – 9.en_US
dc.identifier.citedreferenceSingh G, Mithal A, Kahler K, Shetzline M, Triadafilopoulos G. Patients with irritable bowel syndrome have a high risk of developing colon ischemia [abstract]. Gut 2004; 53 (Suppl. VI): A66.en_US
dc.identifier.citedreferenceJoelsson B, Shetzline MA, Cunningham S. Tegaserod and ischemic colitis. New Engl J Med 2004; 351: 1363.en_US
dc.identifier.citedreferenceBrinker AD, Mackey AC, Prizont R. Tegaserod and ischemic colitis. N Engl J Med 2004; 351: 1361 – 4.en_US
dc.identifier.citedreferenceDiBaise JK. Tegaserod‐associated ischemic colitis. Pharmacotherapy 2005; 25: 620 – 5.en_US
dc.identifier.citedreferenceWooltorton E. Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia. CMAJ 2004; 170: 1908.en_US
dc.identifier.citedreferenceHiggins PD, Davis KJ, Laine L. Systematic review: the epidemiology of ischaemic colitis. Aliment Pharmacol Ther 2004; 19: 729 – 38.en_US
dc.identifier.citedreferenceMorganroth J, Ruegg PC, Dunger‐Baldauf C, Appel‐Dingemanse S, Bliesath H, Lefkowitz M. Tegaserod, a 5‐hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 2002; 97: 2321 – 7.en_US
dc.identifier.citedreferenceAnderson JL, May HT, Bair TL, Muhlestein JB, Horne BD, Carlquist JF. Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case‐control study. J Cardiovasc Pharmacol Ther 2009; 14: 170 – 5.en_US
dc.identifier.citedreferenceBusti AJ, Murillo JR Jr, Cryer B. Tegaserod‐induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004; 24: 526 – 31.en_US
dc.identifier.citedreferenceChan KY, de Vries R, Leijten FP, et al. Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries. Eur J Pharmacol 2009; 619: 61 – 7.en_US
dc.identifier.citedreferenceScarpellini E, Tack J. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs 2008; 17: 1663 – 70.en_US
dc.identifier.citedreferenceAlizyme. Press release: Results from Renzapride. April 2008. Available at: http://www.alizyme.com/alizyme/media/press/show.jsp?ref=128. Accessed December 14, 2010.en_US
dc.identifier.citedreferenceCamilleri M, McKinzie S, Fox J, et al. Effect of renzapride on transit in constipation‐predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004; 2: 895 – 904.en_US
dc.identifier.citedreferenceGeorge AM, Meyers NL, Hickling RI. Clinical trial: renzapride therapy for constipation‐predominant irritable bowel syndrome–multicentre, randomized, placebo‐controlled, double‐blind study in primary healthcare setting. Aliment Pharmacol Ther 2008; 27: 830 – 7.en_US
dc.identifier.citedreferenceSpiller RC, Meyers NL, Hickling RI. Identification of patients with non‐d, non‐C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Dig Dis Sci 2008; 53: 3191 – 200.en_US
dc.identifier.citedreferenceTack J, Middleton SJ, Horne MC, et al. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation‐predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 1655 – 65.en_US
dc.identifier.citedreferenceMeyers NL, Hickling RI. The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome. J Int Med Res 2007; 35: 848 – 66.en_US
dc.identifier.citedreferenceMackie AD, Ferrington C, Cowan S, Merrick MV, Baird JD, Palmer KR. The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment Pharmacol Ther 1991; 5: 135 – 42.en_US
dc.identifier.citedreferenceMotilex Summary of Product Characteristics. Draft, November 2007.en_US
dc.identifier.citedreferenceKaramanolis G, Tack J. Promotility medications – now and in the future. Dig Dis 2006; 24: 297 – 307.en_US
dc.identifier.citedreferenceMoayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non‐ulcer dyspepsia. Cochrane Database Syst Rev 2011; CD001960.en_US
dc.identifier.citedreferenceTonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004; 19: 379 – 90.en_US
dc.identifier.citedreferenceCorinaldesi R, Stanghellini V, Raiti C, Zarabini E, Rea E, Paparo GF. Effects of chronic oral administration of clebopride and metoclopramide on gastric emptying of solids in patients with functional dyspepsia. Curr Ther Res 1985; 38: 790 – 7.en_US
dc.identifier.citedreferenceSabbatini F, Minieri M, Manzi G, Piai G, D'Angelo V, Mazzacca G. Clinical efficacy and safety of cisapride and clebopride in the management of chronic functional dyspepsia: a double‐blind, randomized study. Ital J Gastroenterol 1991; 23: 1 – 4.en_US
dc.identifier.citedreferenceMartinez‐Martin P. Transient dyskinesia induced by clebopride. Mov Disord 1993; 8: 125 – 6.en_US
dc.identifier.citedreferenceIndo T, Ando K. Metoclopramide‐induced Parkinsonism. Clinical characteristics of ten cases. Arch Neurol 1982; 39: 494 – 6.en_US
dc.identifier.citedreferenceSempere AP, Duarte J, Garcia F, Cabezas C, Coria F, Claveria LE. An estimate of the risk of movement disorders associated with the chronic use of clebopride. Mov Disord 1996; 11: 582 – 3.en_US
dc.identifier.citedreferenceKim KS, Shin WH, Park SJ, Kim EJ. Effect of clebopride, antidopaminergic gastrointestinal prokinetics, on cardiac repolarization. Int J Toxicol 2007; 26: 25 – 31.en_US
dc.identifier.citedreferenceYoshida N, Omoya H, Oka M, Furukawa K, Ito T, Karasawa T. AS‐4370, a novel gastrokinetic agent free of dopamine D2 receptor antagonist properties. Arch Int Pharmacodyn Ther 1989; 300: 51 – 67.en_US
dc.identifier.citedreferenceYoshida N, Ito T, Karasawa T, Itoh Z. AS‐4370, a new gastrokinetic agent, enhances upper gastrointestinal motor activity in conscious dogs. J Pharmacol Exp Ther 1991; 257: 781 – 7.en_US
dc.identifier.citedreferenceYoshida N, Ito T. Mosapride citrate (AS‐4370), a new gastroprokinetic agent, is a partial 5‐HT4 receptor agonist in the gut. Neurogastroenterol Motil 1994; 6: 197 – 204.en_US
dc.identifier.citedreferenceYoshida N, Omoya H, Kato S, Ito T. Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneimittelforschung 1993; 43: 1078 – 83.en_US
dc.identifier.citedreferenceHallerback BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo‐controlled, randomized study. Aliment Pharmacol Ther 2002; 16: 959 – 67.en_US
dc.identifier.citedreferenceCarlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 1997; 282: 220 – 7.en_US
dc.identifier.citedreferenceToga T, Kohmura Y, Kawatsu R. The 5‐HT(4) agonists cisapride, mosapride, and CJ‐033466, a Novel potent compound, exhibit different human ether‐a‐go‐go‐related gene (hERG)‐blocking activities. J Pharmacol Sci 2007; 105: 207 – 10.en_US
dc.identifier.citedreferenceMushiroda T, Douya R, Takahara E, Nagata O. The involvement of flavin‐containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab Dispos 2000; 28: 1231 – 7.en_US
dc.identifier.citedreferenceKatoh T, Saitoh H, Ohno N, et al. Drug interaction between mosapride and erythromycin without electrocardiographic changes. Jpn Heart J 2003; 44: 225 – 34.en_US
dc.identifier.citedreferenceEndo J, Nomura M, Morishita S, et al. Influence of mosapride citrate on gastric motility and autonomic nervous function: evaluation by spectral analyses of heart rate and blood pressure variabilities, and by electrogastrography. J Gastroenterol 2002; 37: 888 – 95.en_US
dc.identifier.citedreferenceHorri S, Takeda T, Yasuyuki F, et al. Clinical study on safety of mosapride in combination therapy with psychiatric drugs. Rinsho Iyaku 2000; 16: 153.en_US
dc.identifier.citedreferenceOhki R, Takahashi M, Mizuno O, et al. Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia. Pacing Clin Electrophysiol 2001; 24: 119 – 21.en_US
dc.identifier.citedreferenceBriejer MR, Meulemans AL, Bosmans JP. In vitro pharmacology of the novel enterokinetic R093877. Gastroenterology 1997; 112: A705.en_US
dc.identifier.citedreferenceCamilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo‐controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 2344 – 54.en_US
dc.identifier.citedreferenceEmmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002; 16: 1347 – 56.en_US
dc.identifier.citedreferenceQuigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation–a 12‐week, randomized, double‐blind, placebo‐controlled study. Aliment Pharmacol Ther 2009; 29: 315 – 28.en_US
dc.identifier.citedreferenceTack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58: 357 – 65.en_US
dc.identifier.citedreferenceTack J, Ausma J, Kerstens R, Vandeplassche L. Safety and tolerability of prucalopride (Resolor ® ) in patients with chronic constipation: Pooled data from three pivotal phase III studies [Abstract T1322]. Gastroenterology 2008; 134: A530 – 1.en_US
dc.identifier.citedreferenceCamilleri M, Beyens G, Kerstens R, Vandeplassche L. Long‐term follow‐up of safety and satisfaction with bowel function in response to oral prucalopride in patients with chronic constipation [Abstract]. Gastroenterology 2009; 136 ( Suppl. 1 ): 160.en_US
dc.identifier.citedreferenceBoyce M, Kerstens R, Beyens G, Ausma J, Vandeplassche L. Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double‐blind, placebo‐controlled, cross‐over trials [Abstract]. Gastroenterology 2009; 136 ( Suppl. 1 ): T1265.en_US
dc.identifier.citedreferenceCamilleri M, Kerstens R, Beyens G, Robinson P, Vandeplassche L. A double‐blind, placebo‐controlled trial to evaluate the safety and tolerability of prucalopride oral solution in constipated elderly patients living in a nursing facility [Abstract]. Gastroenterology 2009; 136 ( Suppl. 1 ): 240.en_US
dc.identifier.citedreferenceGoldberg MR, Li YP, Pitzer K, Johanson JF, Mangel A, Kitt MM. TD‐5108 a selective 5‐HT4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation. Gastroenterology 2008; 134: A547.en_US
dc.identifier.citedreferenceManini ML, Camilleri M, Goldberg M, et al. Effects of velusetrag (TD‐5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010; 22: 42 – 9.en_US
dc.identifier.citedreferenceTheravance. Data on file.en_US
dc.identifier.citedreferenceDennis D, Palme M, Irwin I, Druzgala P, Teichman S. ATI‐7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dogs. Gastroenterology 2004; 126: A641.en_US
dc.identifier.citedreferencePalme M, Milner PG, Ellis DJ, Marmon T, Canafax DM. A Novel Gastrointestinal Prokinetic, ATI‐7505, Increased Spontaneous Bowel Movements (Sbms) in a Phase II, Randomized, Placebo‐Controlled Study of Patients With Chronic Idiopathic Constipation (CIC). Gastroenterology 2010; 138: S128 – 9.en_US
dc.identifier.citedreferenceAryx Therapeutics. ATI‐7505 product fact sheet.en_US
dc.identifier.citedreferenceAryx Therapeutics. ATI‐7505 ‐ Gastrointestinal Disorders. Addressing safety issues of first generation drugs. Available at: http://www.aryx.com/wt/page/ati7505. Accessed December 14, 2010.en_US
dc.identifier.citedreferenceEuropean Agency for the Evaluation of Medicinal Products. Cisapride: Summary of product characteristics. 2002. Available at: www.ema.europa.eu/pdfs/human/referral/cisapride/2484402en.pdf.en_US
dc.identifier.citedreferenceZhou H, Herron J, Clyde C, Lee P, Mechlinski W, Pesco‐Koplowitz L. Pharmacokinetic profile of cisapride 20 mg after once‐ and twice‐daily dosing. Clin Ther 1998; 20: 292 – 8.en_US
dc.identifier.citedreferenceYamamoto T, Takano K, Sanaka M, et al. Pharmacokinetic characteristics of cisapride in elderly patients. Int J Clin Pharmacol Ther 1998; 36: 432 – 4.en_US
dc.identifier.citedreferenceAppel‐Dingemanse S, Lemarechal MO, Kumle A, Hubert M, Legangneux E. Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5‐HT4 receptor agonist, following oral and intravenous administration. Br J Clin Pharmacol 1999; 47: 483 – 91.en_US
dc.identifier.citedreferenceMims USA. Zelnorm ‐ Detailed Prescribing Information. Available at: http://www.mims.com/USA/drug/info/Zelnorm/Zelnorm%20Tablet?q=tegaserod&type=full. Accessed November 9, 2011.en_US
dc.identifier.citedreferenceVickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V. In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos 2001; 29: 1269 – 76.en_US
dc.identifier.citedreferenceEuropean Medicines Agency. Refusal Assessment Report for Zelnorm. Doc.Ref.: EMEA/229387/2007. 2006. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000621/WC500058849.pdf. Accessed November 9, 2011.en_US
dc.identifier.citedreferenceMeyers NL, Hickling RI. Pharmacology and metabolism of renzapride: a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D 2008; 9: 37 – 63.en_US
dc.identifier.citedreferenceRobinson PR, Jones MD, Maddock J, Rees LW. Simultaneous determination of clebopride and a major metabolite N‐desbenzylclebopride in plasma by capillary gas chromatography‐negative‐ion chemical ionization mass spectrometry. J Chromatogr 1991; 564: 147 – 61.en_US
dc.identifier.citedreferenceMims Indonesia. Clast ‐ Detailed Prescribing Information. Available at: http://www.mims.com/Indonesia/drug/info/Clast/Clast%20coated%20tab?type=full#Actions ≤ http://www.mims.com/Indonesia/drug/info/Clast/Clast%20coated%20tab?type=full ≥. Accessed December 8, 2011.en_US
dc.identifier.citedreferenceSun H, Scott DO. Metabolism of 4‐aminopiperidine drugs by cytochrome P450s: molecular and quantum mechanical insights into drug design. ACS Med Chem Lett 2011; 2: 638 – 43.en_US
dc.identifier.citedreferenceAchtert G, Borchers F, Finner E, Hausleiter HJ. Metabolism of clebopride in animals and man. In: Poster presented at the 12th European Workshop on Drug Metabolism; 1990; Basel, Switzerland; 1990.en_US
dc.identifier.citedreferenceSakashita M, Mizuki Y, Yamaguchi T, Miyazaki H, Sekine Y. Pharmacokinetics of the gastrokinetic agent mosapride citrate after intravenous and oral administrations in dogs and monkeys. Arzneimittelforschung 1993; 43: 864 – 6.en_US
dc.identifier.citedreferenceSakashita M, Yamaguchi T, Miyazaki H, et al. Pharmacokinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects. Arzneimittelforschung 1993; 43: 867 – 72.en_US
dc.identifier.citedreferenceDianippon Pharma. Mosapride package insert.en_US
dc.identifier.citedreferenceBhan CS, Saraswat R. Short review of mosapride: a prokinetic agent. Journal of Global Pharma Technology 2011; 3: 1 – 4.en_US
dc.identifier.citedreferenceShire‐Movetis. Resolor (prucalopride) Summary of product characteristics. October 2009. Available at: http://www.medicines.org.uk/EMC/history/23206/SPC/Resolor+2mg+film-coated+tablets#03/02/2012 to Current.en_US
dc.identifier.citedreferenceBowersox SS, Lightning LK, Rao S, et al. Metabolism and pharmacokinetics of naronapride (ATI‐7505), a serotonin 5‐HT(4) receptor agonist for gastrointestinal motility disorders. Drug Metab Dispos 2011; 39: 1170 – 80.en_US
dc.identifier.citedreferenceChen SD, Kao CH, Chang CS, Chen GH. Salivary function in patients with reflux esophagitis: effect of cisapride. J Nucl Med 1998; 39: 1449 – 52.en_US
dc.identifier.citedreferenceOrr WC, Chen CL, Sloan S. The role of age and salivation in acid clearance in symptomatic patients with gastro‐oesophageal reflux disease. Aliment Pharmacol Ther 2001; 15: 1385 – 8.en_US
dc.identifier.citedreferenceCeccatelli P, Janssens J, Vantrappen G, Cucchiara S. Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients. Gut 1988; 29: 631 – 5.en_US
dc.identifier.citedreferenceCorazziari E, Bontempo I, Anzini F. Effects of cisapride on distal esophageal motility in humans. Dig Dis Sci 1989; 34: 1600 – 5.en_US
dc.identifier.citedreferenceCucchiara S, Staiano A, Boccieri A, et al. Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro‐oesophageal reflux disease. Gut 1990; 31: 21 – 5.en_US
dc.identifier.citedreferencePaterson WG, Wang H, Beck IT. The effect of cisapride in patients with reflux esophagitis: an ambulatory esophageal manometry/pH‐metry study. Am J Gastroenterol 1997; 92: 226 – 30.en_US
dc.identifier.citedreferenceHorowitz M, Maddox A, Harding PE, et al. Effect of cisapride on gastric and esophageal emptying in insulin‐dependent diabetes mellitus. Gastroenterology 1987; 92: 1899 – 907.en_US
dc.identifier.citedreferenceGardner JD, Rodriguez‐Stanley S, Robinson M, Miner PB, Jr. Cisapride inhibits meal‐stimulated gastric acid secretion and post‐prandial gastric acidity in subjects with gastro‐oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 1819 – 29.en_US
dc.identifier.citedreferenceInauen W, Emde C, Weber B, et al. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study. Gut 1993; 34: 1025 – 31.en_US
dc.identifier.citedreferenceKatschinski M, Schirra J, Arnold R. The efficacy of a 40‐mg extended‐release formulation of cisapride in the treatment of patients with gastro‐oesophageal reflux. Aliment Pharmacol Ther 2000; 14: 113 – 22.en_US
dc.identifier.citedreferencePouderoux P, Kahrilas PJ. A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis. Aliment Pharmacol Ther 1995; 9: 661 – 6.en_US
dc.identifier.citedreferenceGilbert RJ, Dodds WJ, Kahrilas PJ, Hogan WJ, Lipman S. Effect of cisapride, a new prokinetic agent, on esophageal motor function. Dig Dis Sci 1987; 32: 1331 – 6.en_US
dc.identifier.citedreferenceSmout AJ, Bogaard JW, Grade AC, ten Thije OJ, Akkermans LM, Wittebol P. Effects of cisapride, a new gastrointestinal prokinetic substance, on interdigestive and postprandial motor activity of the distal oesophagus in man. Gut 1985; 26: 246 – 51.en_US
dc.identifier.citedreferenceDegen L, Petrig C, Studer D, Schroller S, Beglinger C. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005; 17: 821 – 6.en_US
dc.identifier.citedreferenceHarish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P. Effect of tegaserod on colonic transit time in male patients with constipation‐predominant irritable bowel syndrome. J Gastroenterol Hepatol 2007; 22: 1183 – 9.en_US
dc.identifier.citedreferenceBovero E, Poletti M, Vigneri S. The effect of clebopride on esophageal motility: a double‐blind randomized manometric study. Curr Ther Res 1989; 46: 895 – 901.en_US
dc.identifier.citedreferenceRuth M, Hamelin B, Rohss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro‐oesophageal reflux disease. Aliment Pharmacol Ther 1998; 12: 35 – 40.en_US
dc.identifier.citedreferenceWallin L, Kruse‐Andersen S, Madsen T, Boesby S. Effect of cisapride on the gastro‐oesophageal function in normal human subjects. Digestion 1987; 37: 160 – 5.en_US
dc.identifier.citedreferenceFinizia C, Lundell L, Cange L, Ruth M. The effect of cisapride on oesophageal motility and lower sphincter function in patients with gastro‐oesophageal reflux disease. Eur J Gastroenterol Hepatol 2002; 14: 9 – 14.en_US
dc.identifier.citedreferenceCho YK, Choi MG, Han HW, et al. The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers. J Clin Gastroenterol 2006; 40: 286 – 92.en_US
dc.identifier.citedreferenceVantrappen G, Kortan P, Janssens J. The effect of clebopride on lower esophageal sphincter pressure in normal subjects. Curr Ther Res 1985; 37: 284 – 94.en_US
dc.identifier.citedreferencePehlivanov N, Sarosiek I, Whitman R, Olyaee M, McCallum R. Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro‐oesophageal reflux in patients with oesophagitis: a double‐blind, placebo‐controlled study. Aliment Pharmacol Ther 2002; 16: 743 – 7.en_US
dc.identifier.citedreferenceHolloway RH, Downton J, Mitchell B, Dent J. Effect of cisapride on postprandial gastro‐oesophageal reflux. Gut 1989; 30: 1187 – 93.en_US
dc.identifier.citedreferenceSmythe A, Bird NC, Troy GP, Ackroyd R, Johnson AG. Does the addition of a prokinetic to proton pump inhibitor therapy help reduce duodenogastro‐oesophageal reflux in patients with Barrett's oesophagus? Eur J Gastroenterol Hepatol 2003; 15: 305 – 12.en_US
dc.identifier.citedreferenceChen JD, Ke MY, Lin XM, Wang Z, Zhang M. Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality. Aliment Pharmacol Ther 2000; 14: 1041 – 7.en_US
dc.identifier.citedreferenceBesherdas K, Leahy A, Mason I, Harbord M, Epstein O. The effect of cisapride on dyspepsia symptoms and the electrogastrogram in patients with non‐ulcer dyspepsia. Aliment Pharmacol Ther 1998; 12: 755 – 9.en_US
dc.identifier.citedreferenceBorovicka J, Lehmann R, Kunz P, et al. Evaluation of gastric emptying and motility in diabetic gastroparesis with magnetic resonance imaging: effects of cisapride. Am J Gastroenterol 1999; 94: 2866 – 73.en_US
dc.identifier.citedreferenceJones KL, Horowitz M, Carney BI, Sun WM, Chatterton BE. Effects of cisapride on gastric emptying of oil and aqueous meal components, hunger, and fullness. Gut 1996; 38: 310 – 5.en_US
dc.identifier.citedreferenceLazzaroni M, Sangaletti O, Bianchi Porro G. Effect of cisapride on gastric emptying and ileal transit time of balanced liquid meal in healthy subjects. Digestion 1987; 37: 110 – 3.en_US
dc.identifier.citedreferenceFraser RJ, Horowitz M, Maddox AF, Dent J. Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis – effects of cisapride. Gut 1994; 35: 172 – 8.en_US
dc.identifier.citedreferenceStacher G, Granser GV, Bergmann H, Kugi A, Stacher‐Janotta G, Hobart J. Slow gastric emptying induced by high fat content of meal accelerated by cisapride administered rectally. Dig Dis Sci 1991; 36: 1259 – 65.en_US
dc.identifier.citedreferenceCamilleri M, Malagelada JR, Abell TL, Brown ML, Hench V, Zinsmeister AR. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989; 96: 704 – 12.en_US
dc.identifier.citedreferenceJian R, Ducrot F, Piedeloup C, Mary JY, Najean Y, Bernier JJ. Measurement of gastric emptying in dyspeptic patients: effect of a new gastrokinetic agent (cisapride). Gut 1985; 26: 352 – 8.en_US
dc.identifier.citedreferenceFeldman M, Smith HJ. Effect of cisapride on gastric emptying of indigestible solids in patients with gastroparesis diabeticorum. A comparison with metoclopramide and placebo. Gastroenterology 1987; 92: 171 – 4.en_US
dc.identifier.citedreferenceKawagishi T, Nishizawa Y, Okuno Y, Sekiya K, Morii H. Effect of cisapride on gastric emptying of indigestible solids and plasma motilin concentration in diabetic autonomic neuropathy. Am J Gastroenterol 1993; 88: 933 – 8.en_US
dc.identifier.citedreferenceRichards RD, Valenzuela GA, Davenport KG, Fisher KL, McCallum RW. Objective and subjective results of a randomized, double‐blind, placebo‐controlled trial using cisapride to treat gastroparesis. Dig Dis Sci 1993; 38: 811 – 6.en_US
dc.identifier.citedreferenceCorinaldesi R, Stanghellini V, Raiti C, Rea E, Salgemini R, Barbara L. Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1987; 28: 300 – 5.en_US
dc.identifier.citedreferenceAbell TL, Camilleri M, DiMagno EP, Hench VS, Zinsmeister AR, Malagelada JR. Long‐term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991; 36: 616 – 20.en_US
dc.identifier.citedreferenceStacher G, Bergmann H, Wiesnagrotzki S, et al. Intravenous cisapride accelerates delayed gastric emptying and increases antral contraction amplitude in patients with primary anorexia nervosa. Gastroenterology 1987; 92: 1000 – 6.en_US
dc.identifier.citedreferenceHeyland DK, Tougas G, Cook DJ, Guyatt GH. Cisapride improves gastric emptying in mechanically ventilated, critically ill patients. A randomized, double‐blind trial. Am J Respir Crit Care Med 1996; 154: 1678 – 83.en_US
dc.identifier.citedreferenceMaddern GJ, Jamieson GG, Myers JC, Collins PJ. Effect of cisapride on delayed gastric emptying in gastro‐oesophageal reflux disease. Gut 1991; 32: 470 – 4.en_US
dc.identifier.citedreferenceDi Lorenzo C, Reddy SN, Villanueva‐Meyer J, Mena I, Martin S, Hyman PE. Cisapride in children with chronic intestinal pseudoobstruction. An acute, double‐blind, crossover, placebo‐controlled trial. Gastroenterology 1991; 101: 1564 – 70.en_US
dc.identifier.citedreferenceStacher G, Schernthaner G, Francesconi M, et al. Cisapride versus placebo for 8 weeks on glycemic control and gastric emptying in insulin‐dependent diabetes: a double blind cross‐over trial. J Clin Endocrinol Metab 1999; 84: 2357 – 62.en_US
dc.identifier.citedreferenceMcClure RJ, Kristensen JH, Grauaug A. Randomised controlled trial of cisapride in preterm infants. Arch Dis Child Fetal Neonatal Ed 1999; 80: F174 – 7.en_US
dc.identifier.citedreferenceWei W, Ge ZZ, Lu H, Gao YJ, Hu YB, Xiao SD. Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy. J Gastroenterol Hepatol 2007; 22: 1605 – 8.en_US
dc.identifier.citedreferenceKanaizumi T, Nakano H, Matsui Y, et al. Prokinetic effect of AS‐4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol 1991; 41: 335 – 7.en_US
dc.identifier.citedreferenceYamada M, Hongo M, Okuno Y, et al. Effect of AS‐4370 on gastric motility in patients with diabetic autonomic neuropathy. J Smooth Muscle Res 1992; 28: 153 – 8.en_US
dc.identifier.citedreferenceAsai H, Udaka F, Hirano M, et al. Increased gastric motility during 5‐HT4 agonist therapy reduces response fluctuations in Parkinson's disease. Parkinsonism Relat Disord 2005; 11: 499 – 502.en_US
dc.identifier.citedreferenceManini ML, Camilleri M, Goldberg M, et al. Effects of Velusetrag (TD‐5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010; 22: 42 – 9.en_US
dc.identifier.citedreferenceTack J, Broeckaert D, Coulie B, Janssens J. The influence of cisapride on gastric tone and the perception of gastric distension. Aliment Pharmacol Ther 1998; 12: 761 – 6.en_US
dc.identifier.citedreferenceManes G, Dominguez‐Munoz JE, Leodolter A, Malfertheiner P. Effect of cisapride on gastric sensitivity to distension, gastric compliance and duodeno‐gastric reflexes in healthy humans. Dig Liver Dis 2001; 33: 407 – 13.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt5011.pdf
Size:
264.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.